A mechanism for localized dynamics-driven activation in Bruton's tyrosine kinase

被引:2
作者
Qiu, Simei [1 ,2 ]
Liu, Yunfeng [1 ]
Li, Quhuan [1 ,2 ,3 ]
机构
[1] South China Univ Technol, Inst Biomech, Sch Biosci & Bioengn, Guangzhou, Peoples R China
[2] South China Univ Technol, Guangdong Prov Engn & Technol Res Ctr Biopharmace, Guangzhou, Peoples R China
[3] South China Univ Technol, Sch Biosci & Bioengn, Guangzhou 510006, Guangdong, Peoples R China
来源
ROYAL SOCIETY OPEN SCIENCE | 2021年 / 8卷 / 08期
基金
中国国家自然科学基金;
关键词
activation mechanism; Bruton's tyrosine kinase; T474M mutation; X-LINKED AGAMMAGLOBULINEMIA; IRREVERSIBLE INHIBITORS; TARGETING BTK; IBRUTINIB; DISCOVERY; MUTATION; PATHWAY; BINDING; CANCER; CELLS;
D O I
10.1098/rsos.210066
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Bruton's tyrosine kinase (BTK) plays a vital role in mature B-cell proliferation, development and function. Its inhibitors have gradually been applied for the treatment of many B-cell malignancies. However, because of treatment-associated drug resistance or low efficacy, it is urgent to develop new inhibitors and/or improve the efficacy of current inhibitors, where finding the intrinsic activation mechanism becomes the key to solve this problem. Here, we used BTK T474M mutation as a resistance model for inhibitors to study the mechanism of BTK activation and drug resistance by free molecular dynamics simulations. The results showed that the increase of kinase activity of T474M mutation is coming from the conformation change of the activation ring and ATP binding sites located in BTK N-terminus region. Specifically, the Thr(474) mutation changed the structure of A-loop and stabilized the binding site of ATP, thus promoting the catalytic ability in the kinase domain. This localized dynamics-driven activation mechanism and resistance mechanism of BTK may provide new ideas for drug development in B-cell malignancies.
引用
收藏
页数:11
相关论文
共 42 条
  • [21] A Mechanism for Localized Dynamics-driven Affinity Regulation of the Binding of von Willebrand Factor to Platelet Glycoprotein Ibα
    Liu, Guangjian
    Fang, Ying
    Wu, Jianhua
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2013, 288 (37) : 26658 - 26667
  • [22] Developing Irreversible Inhibitors of the Protein Kinase Cysteinome
    Liu, Qingsong
    Sabnis, Yogesh
    Zhao, Zheng
    Zhang, Tinghu
    Buhrlage, Sara J.
    Jones, Lyn H.
    Gray, Nathanael S.
    [J]. CHEMISTRY & BIOLOGY, 2013, 20 (02): : 146 - 159
  • [23] Crystal structure of Bruton's tyrosine kinase domain suggests a novel pathway for activation and provides insights into the molecular basis of X-linked agammaglobulinemia
    Mao, C
    Zhou, M
    Uckun, FM
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (44) : 41435 - 41443
  • [24] Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases
    Marcotte, Douglas J.
    Liu, Yu-Ting
    Arduini, Robert M.
    Hession, Catherine A.
    Miatkowski, Konrad
    Wildes, Craig P.
    Cullen, Patrick F.
    Hong, Victor
    Hopkins, Brian T.
    Mertsching, Elisabeth
    Jenkins, Tracy J.
    Romanowski, Michael J.
    Baker, Darren P.
    Silvian, Laura F.
    [J]. PROTEIN SCIENCE, 2010, 19 (03) : 429 - 439
  • [25] Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain
    Mohamed, Abdalla J.
    Yu, Liang
    Backesjo, Carl-Magnus
    Vargas, Leonardo
    Faryal, Rani
    Aints, Alar
    Christensson, Birger
    Berglof, Anna
    Vihinen, Mauno
    Nore, Beston F.
    Smith, C. I. Edvard
    [J]. IMMUNOLOGICAL REVIEWS, 2009, 228 : 58 - 73
  • [26] X-linked agammaglobulinemia - A clinical and molecular analysis
    Ochs, HD
    Smith, CIE
    [J]. MEDICINE, 1996, 75 (06) : 287 - 299
  • [27] Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase
    Pan, Zhengying
    Scheerens, Heleen
    Li, Shyr-Jiann
    Schultz, Brian E.
    Sprengeler, Paul A.
    Burrill, L. Chuck
    Mendonca, Rohan V.
    Sweeney, Michael D.
    Scott, Keana C. K.
    Grothaus, Paul G.
    Jeffery, Douglas A.
    Spoerke, Jill M.
    Honigberg, Lee A.
    Young, Peter R.
    Dalrymple, Stacie A.
    Palmer, James T.
    [J]. CHEMMEDCHEM, 2007, 2 (01) : 58 - 61
  • [28] Discovery of a Gatekeeper Residue in the C-Terminal Tail of the Extracellular Signal-Regulated Protein Kinase 5 (ERK5)
    Pearson, Adam J.
    Fullwood, Paul
    Tapia, Gabriela Toro
    Prise, Ian
    Smith, Michael P.
    Xu, Qiuping
    Jordan, Allan
    Giurisato, Emanuele
    Whitmarsh, Alan J.
    Francavilla, Chiara
    Tournier, Cathy
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (03)
  • [29] Scalable molecular dynamics with NAMD
    Phillips, JC
    Braun, R
    Wang, W
    Gumbart, J
    Tajkhorshid, E
    Villa, E
    Chipot, C
    Skeel, RD
    Kalé, L
    Schulten, K
    [J]. JOURNAL OF COMPUTATIONAL CHEMISTRY, 2005, 26 (16) : 1781 - 1802
  • [30] Advances in kinase targeting: current clinical use and clinical trials
    Rask-Andersen, Mathias
    Zhang, Jin
    Fabbro, Doriano
    Schioth, Helgi B.
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 2014, 35 (11) : 60 - 76